John Parkinson

Ryan Shields, PharmD, MS, discusses the challenges of incorporating newer antibiotics for Gram-negative infections, how he is using broad-spectrum antimicrobial agents for these infections, and the factors he looks for in considering new agents.

Monica V. Mahoney PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP, FMSHP, provides insights on the outpatient side of therapy, including treating outpatients for Gram-negative infections.

Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc, offers some insights on the latest diagnostics, susceptibility testing for newer antimicrobials, and how infectious disease clinicians and laboratory professionals can collaborate on challenging cases.

The Los Angeles County Department of Public Health updated the public on the specific local case and reminds everyone of the importance of vaccination to protect the community.

Daniela Weiskopf, PhD, of the La Jolla Institute for Immunology, discusses her research in this area including the unique findings and pathways for therapeutics.

Merck reported the results for its phase 3 trial for its vaccine, Capvaxive, which was found to be noninferior to the pneumococcal 23-valent polysaccharide vaccine (PPSV23) for each of the 12 serotypes shared between the vaccines.

In the second installment of an interview with Jacinda Abdul-Mutakabbir, PharmD, MPH, she continues the discussion around limited to no health care engagement due to these factors, and the importance of translating data from the bench to bedside when looking at disease and infection prevention.

Jacinda Abdul-Mutakabbir, PharmD, MPH, provides insights on her recently published study on this topic and how the 2 are connected.

Michael Herce, MD, MPH, MSCR, discusses this concept and how it works to improve access to healthcare for populations who have been disproportionately burdened by various infectious diseases such as HIV, tuberculosis, and COVID-19.

In the second interview segment with leaders from UNC's Special Pathogen Center, they discuss what it is like to be in the field during an outbreak caring for patients with high-consequence infectious diseases, and offer insights on how well prepared the US is for these situations.

David Margolis, MD discusses his team’s work at UNC looking at combination treatment that includes the cancer drug, vorinostat, and immunotherapy as a potential HIV cure.

This becomes the first state in the United States to do so, and of course, this decision will affect the childhood vaccine schedule in Florida. Infectious Diseases Society of America (IDSA) President, Tina Tan, MD, weighs in on this decision and what this could mean for an increase of vaccine-preventable diseases and who would be vulnerable to them.

Jonathan Parr, MD, MPH, discusses his research about this deadly and burdensome disease and how he and his team identify these parasitic strains with a combination of epidemiologic field work and the latest laboratory technology.

Robert Hopkins, Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID), discusses what patients are asking about with regards to the vaccines and what the general public should continue to know about their medical value.

UNC’s Sarah Rutstein, MD, PhD, discusses her research uncovering the inability of some people to receive HIV prevention medication in both the US and Africa and strategies to address it.

Joseph Eron, MD, provides insights on the unit's international reach as well as some of the important trials it has been involved in, notably the PURPOSE studies involving the landmark trials about lenacapavir for HIV prevention.

UNC’s Benjamin Smith, MD, provides some insights into the logistics and steps behind these complicated and serious missions.

Leaders from the UNC Special Pathogens Response Center discuss how they plan and carry out biopreparedness trainings to address transport and care of patients with high-consequence infectious diseases, such as Ebola or Lassa fever.

Christopher Sellers, MD, discusses its distinct program and diverse professional opportunities and provides some insights as to why many ID trainees stay at the University of North Carolina.

The Institute's Director Myron Cohen, MD, discusses the uniqueness of the institution and its ability to offer research and clinical opportunities globally as well as play a significant role in public health.

Allegheny Health Network’s (AHN) Thomas Walsh, MD, talks about Allegheny General Hospital being recognized as an Infectious Diseases Society of America (IDSA) Center of Excellence and some of the stewardship strategies they are employing to reduce antimicrobial usage.

Deeksha Jandhyala, MD, discusses how her team works to prevent infections and provide clinical assistance for transplant candidates.

George Bchech, MD, details his experience within the AHN ID-CCM fellowship.

In the second episode of Allegheny Health Network’s (AHN) Media Day, Cassandra Oehler, MD, provides insights on HIV care at AHN's Positive Health Clinic (PHC), including the comprehensive services they offer and how they are involved in clinical trials using long-acting injectables.

The comprehensive program provides instruction in both specialties to enable fellows to treat the most critically ill patients.

Jose Alexander, MD, offers insights on these antimicrobial combinations when treating against this bacterium.

If this GSK antibiotic is approved, it will provide a new oral option to patients in the US who are currently relying on injectable treatments.

Emily Olsen, PhD, offers some insights on this underdiagnosed infection, including describing antimicrobial studies, particularly in biofilm and intracellular environments. Her findings look to create a standardized approach for treating all forms of the different presentations of bartonellosis.

Athena Hobbs, PharmD, BCIDP, looked at this issue through the lens of treating urinary tract infections.

Clarametyx Biosciences said its investigational antibody therapy, CMTX-101, which is in a phase 1b/2a study, remains on track for full trial enrollment by the end of 2025.